<DOC>
	<DOCNO>NCT02772276</DOCNO>
	<brief_summary>This study pilot , safety , pharmacokinetic study MB-102 versus iohexol use non-invasive optical renal function monitor ( ORFM ) device normal compromise renal function participant different skin color type .</brief_summary>
	<brief_title>Pharmacokinetics MB-102 Use Non-invasive Optical Renal Function Monitor ( ORFM ) Device Subjects With Normal Impaired Renal Function Range Skin Color Types</brief_title>
	<detailed_description>This clinical study first assess pharmacokinetics function ORFM device participant impair kidney function . In addition , evaluate impact different skin color type readouts ORFM prototype device QuantumLeap Radiance . These data use refine algorithm use ORFM device pivotal trial commercial development . Safety tolerance MB-102 also assess large population subject .</detailed_description>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Female participant must childbearing potential willing use studydesignated contraception method screen followup visit Males must willing practice abstinence utilize adequate contraception dose day least 7 day postdose Minimum body weight 50 kg ( men ) 48 kg ( woman ) Normal nonclinically significant screen baseline 12 lead ECG opinion PI Adequate venous access sufficient allow blood sample per protocol requirement Cohort 1 3 Healthy determine medical history , clinically significant finding screen baseline physical exam , vital sign clinical laboratory panel condition could adversely impact participant 's participation safety , conduct study interfere study assessment eGFR ( CKDEPI equation ) â‰¥60 ml/min/1.73m2 ( normal Stage 2 CKD ) time screen Cohort 2 4 Stable renal function opinion PI eGFR ( CKDEPI equation ) 15 59 mL/min/1.73m2 time screen Stable use immunosuppressant medication ( applicable ) Cohort 5 eGFR ( CKDEPI equation ) &lt; 15 mL/min/1.73m2 ( ESRD ) time screen Stable use immunosuppressant medication ( applicable ) Women pregnant , lactate plan become pregnant study , woman childbearing potential unwilling use barrier method birth control Intolerant venipuncture Recent donation loss blood plasma : 100 mL 499 mL within 30 day prior initial dose study medication ; 499 mL within 56 day prior initial dose study medication Participation another interventional trial within 30 day screen concurrently enrol medical research study could impact result study History drug alcohol abuse within past year Any food allergy , intolerance , restriction special diet , opinion Principal Investigator , could contraindicate subject 's participation study Allergies 2 class drug Stable use ( change within 30 day ) prescription OTC medication NSAID use within 2 day dose day History coagulation bleed disorder judgement investigator place participant undue risk study related procedure disorder Homozygous sickle cell disease Have know thyroid disorder Have pheochromocytoma Currently Coumadin ( warfarin ) INR &gt; 4 screen Current history AIDS HIV Hepatitis B antigen positive , C antibody positive Any characteristic , opinion investigator , make subject poor candidate participation clinical trial Significant scaring , tattoos alteration pigmentation sternum would alter sensor reading versus area skin Cohort 1 3 History significant cardiovascular disease , heart failure , myocardial infarction past 3 month , pulmonary , hematologic , endocrine , hepatobiliary , nephrologic , immunologic , dermatologic , neurologic ( include history stroke and/or seizure disorder ) , psychological , musculoskeletal disease , diagnosis cancer past 2 year deem clinically significant unstable Principal Investigator ; Note : history gallstone kidney stone exclude long condition acute within 30 day dose . Cohort 2 4 Stage 5 chronic kidney disease ( CKD ) Recent ( within 3 month ) significant medical condition surgical procedure include myocardial infarction , laparoscopic procedure , medical invention Doses prednisone great 10 mg/day within last 90 day Cohort 5 Recent ( within 3 month ) significant medical condition surgical procedure include myocardial infarction , laparoscopic procedure , medical invention Doses prednisone great 10 mg/day within last 90 day</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Glomerular Filtration Rate</keyword>
</DOC>